Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Albert Bourla, CEO of Pfizer, speaking on Squawk on the Street at the World Economic Forum in Davos, Switzerland on Jan. 20, 2026.Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December.The pharmaceutical giant is looking to longer-term investments in its pipeline, including its $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product ...